Winners And Losers in CLL at ASCO '13 NEW YORK (TheStreet) -- New products in development for chronic lymphocytic leukemia (CLL), an incurable B-cell cancer, will transform the treatment of this disease over the next few years. CLL offers a big market opportunity as more than 150,000 people in the U.S. and Europe have the disease, and about a third of these require first or second-line therapy. After PD-1/PD-L1 immunotherapy, CLL ...
June 10, 2013 - TheStreet.com